We recently compiled a list of the 10 Stocks That Underperformed Last Week. In this article, we are going to take a look at ...
Coeur Mining (NYSE:CDE – Free Report) had its target price decreased by Roth Mkm from $8.50 to $8.25 in a report released on ...
Stock analysts at Cormark issued their Q1 2025 earnings estimates for Coeur Mining in a research note issued to investors on ...
公司于2023年9月向CDE递交了甲苯磺酸艾多沙班的药品注册申请并获得受理。目前,京圣药业尚未完成GMP符合性检查,正在准备申请相关检查。根据CDE网站公示,截止公告日,除了公司外,国内已有6家厂家获得该原料药的CDE技术审评通过。由于市场环境变化等 ...
We recently compiled a list of the These 10 Firms Were Heavily Hit on Friday. In this article, we are going to take a look at ...
1h
格隆汇 on MSN天宇股份(300702.SZ):甲苯磺酸艾多沙班原料药通过CDE审评格隆汇2月24日丨天宇股份(300702.SZ)公布,公司全资子公司浙江京圣药业有限公司(简称“京圣药业”)甲苯磺酸艾多沙班原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。
1h
每日经济新闻 on MSN天宇股份:全资子公司原料药通过CDE审评每经AI快讯,2月24日,天宇股份公告称,公司全资子公司浙江京圣药业有限公司的甲苯磺酸艾多沙班原料药于近日通过国家药品监督管理局药品审评中心审评。该药品用于非瓣膜性房颤成人患者预防卒中和体循环栓塞,以及成人深静脉血栓和肺栓塞的治疗和预防复发。甲苯磺酸 ...
Raymond James upgraded Coeur Mining (CDE) to Outperform from Market Perform with a price target of $8.25, up from $7.75.Discover the Best ...
The second annual Haskell Ag Lab CDE invitational was held Jan. 29-30. There were 180 participants from 15 schools in three ...
CHICAGO — CHICAGO — Coeur Mining Inc. (CDE) on Wednesday reported fourth-quarter net income of $37.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results